Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
The principle of gene-directed enzyme prodrug therapy (GDEPT) has existed for many years but, while simple in concept, the effective practical application of this therapy has proven to be challenging. Improvements in the efficacy of GDEPT have been achieved principally through the choice and development of more effective vectors, by optimizing and controlling gene expression and by increasing the activity of the delivered enzyme through mutation. While innovation continues in this field, the pioneering GDEPT systems designed to treat glioma and prostate cancer have completed or are now entering late-stage clinical trials, respectively. As the pace of innovation in GDEPT technology far exceeds its clinical application, these initial products are anticipated to be replaced by next-generation biologicals. This review highlights recent progress in the strategies and development of GDEPT and summarizes the status of current clinical trials. With the first GDEPT product for treatment of resected gliomas poised to gain marketing approval, a new era in cancer gene medicine is emerging.
Both
Gerald W
GW
Biotech Equity Partners, NSW, Australia. Gerry.Both@biotechequitypartners.com.au
D000818:Animals; D004798:Enzymes / Q000378:metabolism*; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*
D004798:Enzymes; D011355:Prodrugs